We are proud to announce that Synexa Life Sciences has been awarded Gyrolab CRO certification, recognising our expertise in advanced immunoassay development and analysis using Gyros’ automated platform.
This certification marks an important milestone for our bioanalytical team, who have worked closely with Gyros Protein Technologies to validate and optimise workflows that meet the highest industry standards. The low sample consumption, high sensitivity, and broad dynamic of Gyrolab platform range provide a critical edge in preclinical and clinical studies, enabling Synexa to tackle complex challenges with precision and efficiency. The Synexa team in Turku, with its deep expertise in high-performance bioanalytical technologies, has been at the forefront of leveraging Gyrolab platform’s capabilities. The platform’s low sample consumption, high sensitivity, and broad dynamic range make it an invaluable tool for preclinical and clinical studies, particularly where sample volume is limited.
By integrating Gyrolab technology, we offer faster turnaround times and enhanced assay reproducibility, helping clients to progress their drug development programmes more efficiently.
Jordyn van Teylingen, Global Head of Bioanalysis & Soluble Biomarkers at Synexa, explains:
“At Synexa, patient-centricity is at the heart of everything we do. Gyrolab® stands out as a vital tool, as it offers nanoliter-scale precision and an automated workflow—both of which minimize patient burden while accelerating and enhancing the efficiency of our results.”
Synexa and Gyrolab have built a strong partnership over the years, driven by a shared commitment to innovation and excellence.
“Gyrolab is a very reliable partner, and we have received excellent scientific support” says Jordyn van Teylingen.
To learn more about how Synexa can support your research projects, please contact us.
